Analysis: Bayer immune to pharma's breakup bug?

FRANKFURT (Reuters) – Investors banking on Bayer to embrace a trend in the pharma sector to split off non-core units may be too far ahead of the curve.

Powered by WPeMatico

This entry was posted in World News. Bookmark the permalink.

Comments are closed.